Valneva SE (VALN) Operating Leases (2020 - 2026)
Valneva SE (VALN) posted quarterly Operating Leases of $27.8 million for Q1 2026, down 10.39% year-on-year from $31.0 million in Q1 2025, and down 3.59% on a QoQ basis from $28.8 million in Q4 2025.
Valneva SE (VALN) Operating Leases (2020 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Operating Leases for 7 consecutive years, with $27.8 million the latest figure, recorded in Q1 2026.
- Quarterly Operating Leases fell 10.39% year-over-year to $27.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.8 million (down 10.39% YoY) and the FY2025 annual result came in at $28.8 million, down 12.43% from the prior year.
- Operating Leases fell to $27.8 million in Q1 2026 per VALN's latest filing, from $28.8 million in the prior quarter.
- Over the last five years, Operating Leases for VALN reached as high as $61.0 million in Q4 2022 and fell as low as $27.8 million in Q1 2026.
- A 5-year average of $37.9 million and a median of $31.7 million in 2023 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2023 — Operating Leases plunged 47.09% — and 2025, when it retreated 1.02%.
- Year by year, Operating Leases stood at $61.0 million in 2022, then slumped by 40.33% to $36.4 million in 2023, then fell by 9.47% to $32.9 million in 2024, then retreated by 12.43% to $28.8 million in 2025, then decreased by 3.59% to $27.8 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $27.8 million, $28.8 million, and $29.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 27.80 Mn |
| Dec 31, 2025 | 28.84 Mn |
| Sep 30, 2025 | 28.96 Mn |
| Jun 30, 2025 | 29.47 Mn |
| Mar 31, 2025 | 31.03 Mn |
| Dec 31, 2024 | 32.93 Mn |
| Sep 30, 2024 | 29.60 Mn |
| Jun 30, 2024 | 30.19 Mn |
| Mar 31, 2024 | 31.35 Mn |
| Dec 31, 2023 | 36.38 Mn |
| Sep 30, 2023 | 31.69 Mn |
| Jun 30, 2023 | 31.73 Mn |
| Mar 31, 2023 | 33.63 Mn |
| Dec 31, 2022 | 60.96 Mn |
| Sep 30, 2022 | 59.91 Mn |
| Jun 30, 2022 | 59.10 Mn |
| Mar 31, 2022 | 59.93 Mn |
| Dec 31, 2021 | 64.66 Mn |
| Dec 31, 2020 | 59.27 Mn |